Biotransformation of [14C]-ixazomib in patients with advanced solid tumors: characterization of metabolite profiles in plasma, urine, and feces-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Biotransformation of [14C]-ixazomib in patients with advanced solid tumors: characterization of metabolite profiles in plasma, urine, and feces

Published:2018-08-20 Issue:5 Volume:82 Page:803-814
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Pusalkar Sandeepraj,Plesescu Mihaela,Gupta Neeraj,Hanley Michael,Venkatakrishnan Karthik,Wu Jing-Tao,Xia Cindy,Zhang Xiaoquan,Chowdhury Swapan

Funder

Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/article/10.1007/s00280-018-3671-z/fulltext.html

Reference26 articles.

1. Chauhan D, Tian Z, Zhou B et al (2011) In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res 17(16):5311–5321

2. Kupperman E, Lee EC, Cao Y et al (2010) Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res 70(5):1970–1980

3. Lee EC, Fitzgerald M, Bannerman B et al (2011) Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies. Clin Cancer Res 17(23):7313–7323

4. Merlini G, Sanchorawala V, Zonder JA et al (2014) Long-term outcome of a phase 1 study of the investigational oral proteasome inhibitor (PI) ixazomib at the recommended phase 3 dose (RP3D) in patients (pts) with relapsed or refractory systemic light-chain (AL) amyloidosis (RRAL). Blood 124(21):3450–3450

5. Sanchorawala V, Palladini G, Kukreti V et al (2017) A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood 130(5):597–605

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Rise of Boron-Containing Compounds: Advancements in Synthesis, Medicinal Chemistry, and Emerging Pharmacology;Chemical Reviews;2024-02-21

2. The UHPLC-UV method applied for the forced degradation study of ixazomib and HRMS identification of its degradation products;Journal of Pharmaceutical and Biomedical Analysis;2023-02

3. An update on the safety of ixazomib for the treatment of multiple myeloma;Expert Opinion on Drug Safety;2022-09-02

4. Proteasome Inhibitors and Their Pharmacokinetics, Pharmacodynamics, and Metabolism;International Journal of Molecular Sciences;2021-10-27

5. Direct Carbon Isotope Exchange through Decarboxylative Carboxylation;Journal of the American Chemical Society;2019-01-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3